Apogee Therapeutics, an I&I biologics maker that quickly went public in 2023, said Monday it’s headed toward a Dupixent face-off next year as it looks …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Discover how retina models are revolutionizing rare disease treatment and accelerating drug development.
Targeting hormonal therapy for endometrial cancer is opening up the potential to improve outcomes without overtreating in the molecular era. A dramatic increase in endometrial
What You Should Know: – 98point6 Technologies unveils two major developments: introducing an asynchronous care module to its flagship platform and acquiring the remaining assets